Caricamento quotazioni...
Previsioni
Non sono disponibili dati degli analisti per questa azienda.
Notizie Vai al feed delle notizie
PolyNovo achieves 26% revenue growth and shares rise after strong half-year report
PolyNovo reports group revenue of AUD 68.2m for H1 2026 (+26%) and adjusted EBITDA of AUD 4.7m (+82%), driven by strong growth in the US (75.8% of revenue) and 95 new hospital customers. The share price rose 5.72% to AUD 1.005; gross margin was temporarily pushed down to 88.8% by manufacturing optimization measures. The company plans to complete a new production facility by July 2026 and is preparing a PMA submission for a product to treat full-thickness burns. » Altro su de.investing.com
Polynovo shares jump sharply after CMS proposal for skin substitute reimbursement
Polynovo shares surged after a US CMS proposal for a uniform flat reimbursement of $806 per square inch for skin substitutes. Polynovo said its NovoSorb products should remain profitable under the new model; interim CEO Robyn Elliott sees significant growth potential in the outpatient market. A final decision is expected in November, with implementation planned for January 2026. » Altro su de.investing.com
Dividendi storici Dividendi
Tutte le metriche sui dividendi Tutte le metricheDati finanziari dell'azienda
| (EUR) | giu 2026 | |
|---|---|---|
| Ricavi | 44,45 Mln | - |
| Utile lordo | 15,44 Mln | - |
| Utile netto | 4,44 Mln | - |
| EBITDA | 3,94 Mln | - |
Dati fondamentali
| Metrica | Valore |
|---|---|
Capitalizzazione di mercato | 423,35 Mln € |
Numero di azioni | 690,84 Mln |
Massimo/minimo a 52 settimane | 0,88 € - 0,47 € |
| Dividendi | No |
Beta | 1,34 |
Rapporto P/E | 98,11 |
Rapporto PEG | -2,20 |
Rapporto P/B | 7,92 |
Rapporto P/S | 5,00 |
Profilo aziendale
Polynovo Limited entwickelt Medizinprodukte in den Vereinigten Staaten, Australien, Neuseeland, dem Vereinigten Königreich, Irland, Singapur und international. Das Unternehmen bietet die biologisch abbaubare temporäre Matrix NovoSorb an, die in einer vollständig debridierten, sauberen chirurgischen Wunde verwendet wird, um die Wunde physiologisch zu schließen. Darüber hinaus entwickelt es Syntrel Hernienvorrichtungen für die Hernienreparatur, NovoSorb Dermal Beta Cell Implant, das Pankreasinseln in der Haut beherbergt, und NovoSorb Drug Elution Depots. Das Unternehmen war früher unter dem Namen Calzada Limited bekannt und änderte im November 2014 seinen Namen in Polynovo Limited. Polynovo Limited wurde 1998 gegründet und hat seinen Hauptsitz in Port Melbourne, Australien.
| Nome | Polynovo |
| CEO | Bruce Peatey |
| Sede centrale | Port Melbourne,
vic Stati Uniti |
| Sito web | |
| Settore | Servizi di pubblica utilità |
| Quotazione in borsa | 08/12/2000 |
| Dipendenti | 301 |
Deep Dive
Simboli di borsa
| Borsa | Simbolo |
|---|---|
Australian Securities Exchange Ltd | PNV.AX |
Pnk | CALZF |
Frankfurt | MFJ.F |
Düsseldorf | MFJ.DU |
SIX | MFJ.SW |
München | MFJ.MU |
Scopri gli asset
Gli azionisti di Polynovo investono anche nei seguenti asset
